Foldax Announces Positive One-Year Data on TRIA Mitral Valve
SALT LAKE CITY, June 27, 2025--(BUSINESS WIRE)--Foldax® Inc., a leader in the development of innovative polymer heart valves, today announced compelling one-year results from the India Clinical Trial of the TRIA™ Mitral Valve, showing a good safety profile, sustained hemodynamic performance, and statistically significant improvement in patient quality of life. These are the first one-year outcomes ever presented for a multicenter clinical study of a polymer heart valve worldwide. Results were presented today at New York Valves 2025, the annual conference organized by the Cardiovascular Research Foundation (CRF), and concurrently published in the Journal of the American College of Cardiology (JACC).
Key one-year results from the trial showed:
No valve-related mortality or reinterventions
>50% reduction in mean gradient (9.7 mmHg to 4.5 mmHg) and >90% increase in effective orifice area (0.9 cm² to 1.5 cm²), the highest reported in similar surgical mitral valve studies
24-point improvement in KCCQ score (57.5 to 81.9) and 65% increase in Six-Minute Walk Test distance (298.1 m to 494.8 m), indicating significant improvement in quality of life
The prospective, multicenter trial enrolled 67 patients aged 19 to 67 across eight sites in India, with an average age of 42. Notably, 64% were women, and of these, nearly half were of childbearing age, a significantly larger percentage than typically seen in clinical studies. Seventy-three percent of patients had rheumatic heart disease.
"It is exciting to see the positive clinical outcomes associated with this novel polymer valve," said Isaac George, M.D., Surgical Director of the Heart Valve Center at Columbia University. "This new type of valve sets out to reimagine how a device can address clinical needs that are underserved by current valve solutions."
"I am proud to be the principal investigator in India for this groundbreaking trial and represent the highly esteemed clinical investigators who participated in the study," said Kaushal Pandey, M.D., Principal Investigator of the TRIA Mitral Valve India Clinical Trial and Cardiac Surgeon at P.D. Hinduja Hospital in Mumbai. "The TRIA Mitral Valve provides hope for Indian patients—including younger patients and many women of childbearing age—for whom current valve options often fall short."
Foldax's vision for its novel polymer heart valves is to address the limitations of tissue and mechanical options by making its valves durable, with the future goal of avoiding a requirement for lifelong anticoagulation. TRIA valves incorporate a proprietary polymer—LifePolymer™ —formulated to be calcium-resistant, biostable and biocompatible. The novel polymer material enables TRIA valves to be robotically produced, which is designed to increase manufacturing efficiency and maximize product quality and precision.
"These results validate our strategy of taking heart valve therapy to a new level by bringing innovation to a platform of products that will help patients globally," said Ken Charhut, CEO of Foldax.
The Journal of the American College of Cardiology (JACC) publication can be viewed at: https://doi.org/10.1016/j.jacc.2025.06.017
*The TRIA Mitral Valve is approved for use in India by CDSCO. The TRIA Mitral Valve is for investigational use only and is not available for commercial sale in the U.S.
About Foldax
Headquartered in Salt Lake City, Utah, Foldax is reinventing every aspect of the heart valve—from material to design to manufacturing—to develop surgical and transcatheter valves with the potential to last a lifetime, addressing limitations of tissue and mechanical valves.
Foldax investors include Angel Physicians Fund, Biostar Capital, Caltech, Glenview Capital, Kairos Ventures, Memorial Care Innovation Fund and Sayan Bioventures. For more information on the TRIA Mitral Valve and Foldax's commitment to revolutionizing heart valve care, visit www.Foldax.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250627789323/en/
Contacts
MEDIA CONTACT: Michelle McAdam, Chronic Communications, Inc.michelle@chronic-comm.com (310) 902-1274
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 minutes ago
- Business Wire
Sensorion Announces Its Participation In Upcoming Investor Conferences
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced its participation in upcoming investor conferences to be held in September and October 2025. Nawal Ouzren, Chief Executive Officer of Sensorion, and Laurene Danon, Chief Financial Officer, will attend the following events: 27th Annual H.C. Wainwright Global Investment Conference, to be held in New York City, USA, on September 8-10, 2025. Baird 2025 Global Healthcare Conference, to be held in New York City, USA, on September 9-10, 2025. European Midcap Event (CF&B), to be held at the Four Seasons Hôtel George V in Paris, France, on September 30 and October 1, 2025. Portzamparc Biotech & Health Seminar, taking place virtually on October 1-2, 2025. Chardan's 9 th Annual Genetic Medicines Conference, to be held in New York City, USA, on October 21, 2025. If you would like to meet members of Sensorion's management team at any of these events, please contact us by email at About Sensorion Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. Sensorion's portfolio also comprises programs of a clinical-stage small molecule, SENS-401 (Arazasetron), for the treatment and prevention of hearing loss disorders. Sensorion's small molecule progresses in a Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) for the preservation of residual hearing. Sensorion, with partner Cochlear Limited, completed in 2024 a Phase 2a study of SENS-401 for the residual hearing preservation in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022. Disclaimer This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2024 full year report published on March 14, 2025, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
Business Wire
9 hours ago
- Business Wire
eClinicalWorks Pledges Support to CMS Digital Health Tech Ecosystem Initiative at the White House
WESTBOROUGH, Mass.--(BUSINESS WIRE)-- eClinicalWorks®, the largest ambulatory cloud EHR, is proud to announce its active participation in the CMS Digital Health Tech Ecosystem, an initiative announced today by top health officials at the White House to promote seamless healthcare data sharing and new industry interoperability standards. The Centers for Medicare and Medicaid Services (CMS) and the U.S. Department of Health and Human Services (HHS) are spearheading the initiative to establish a framework for interoperability, enhancing patient and provider access to health information. The aim is to create a more intelligent and personalized healthcare system. 'We pledge to work collaboratively and become a CMS Aligned Network,' said Girish Navani, CEO and cofounder of eClinicalWorks. 'This will empower our providers and patients to have real-time access to health information.' 'eClinicalWorks pledges to enhance our systems, 'Kill the Clipboard,' to make it easy for patients to share information efficiently,' Navani continued. eClinicalWorks Pledges at the White House Event: Network Pledge — CMS Interoperability Framework: eClinicalWorks pledges to implement the CMS Interoperability Framework, empowering patients, providers, and their apps with real-time access. EMR Pledge — Kill the Clipboard: eClinicalWorks pledges to eliminate the use of clipboards by enabling systems to accept patient data via QR codes or Smart Health Cards/Links. For more information on eClinicalWorks interoperability solutions, visit About eClinicalWorks eClinicalWorks was founded in 1999 to help digitize paper charts for ambulatory practices. Today, eClinicalWorks innovates the nation with cloud-based Electronic Health Records and Practice Management solutions. In addition, we help ambulatory practices, specialists, health centers, urgent care facilities, and hospital systems manage their revenue cycle, patient relationships, and Population Health initiatives. More than 180,000 providers and 1 million medical professionals rely upon the power and scalability of the eCW Cloud for flexible clinical documentation, better front-office workflows, and more efficient billing driven by Robotic Process Automation. We combine innovation, leading-edge technology, and a commitment to patient safety to enable practices to grow and thrive amid the challenges of 21st-century healthcare. For more information, visit follow us on Facebook and Twitter, or call (866) 888-6929.
Business Wire
10 hours ago
- Business Wire
Prime Healthcare Achieves National Recognition for Exemplary Social Responsibility by Lown Institute
ONTARIO, Calif.--(BUSINESS WIRE)--Prime Healthcare has been recognized as a national leader in hospital social responsibility, with 46 of its hospitals earning 'A' grades on the 2025-26 Lown Institute Hospitals Index. Among more than 3,500 hospitals evaluated nationwide, Prime hospitals stood out for their exceptional performance in health equity, patient outcomes and value of care—key measures that reflect a hospital's impact on the communities it serves. Recognized for health equity and patient outcomes, 46 Prime hospitals received top 'A' grades on the 2025-26 Lown Index, reflecting the system's commitment to socially responsible care. Share Eight Prime hospitals earned top ranks in their states across various domains, including health equity, patient safety and community impact: Saint Francis Hospital ranked No. 1 in the nation for Pay Equity and #1 in Illinois for Pay Equity Saint Mary of Nazareth Hospital ranked No. 1 in Illinois for Health Equity East Liverpool City Hospital ranked No. 1 in Ohio for Social Responsibility and Pay Equity Garden City Hospital ranked No. 1 in Michigan for Patient Safety Landmark Medical Center ranked No. 1 in Rhode Island for Health Equity, Inclusivity and Pay Equity North Vista Hospital ranked No. 1 in Nevada for Social Responsibility, Health Equity, Community Benefit, Inclusivity and Racial Inclusivity Providence Medical Center ranked No. 1 in Kansas for Social Responsibility Saint Clare's Denville ranked No. 1 in New Jersey for Avoiding Overuse The Lown Institute Hospitals Index is an independent national ranking that evaluates hospitals on more than 50 metrics across equity, value and outcomes—factors often overlooked in traditional hospital ratings. 'Hospitals are facing unprecedented political and financial challenges,' said Vikas Saini, MD, president of the Lown Institute. 'In this uncertain environment, it's more important than ever to support the socially responsible hospitals who are delivering high-quality care to all in their community.' Prime Healthcare continues to strengthen its mission to save and improve hospitals through measurable results. The system's strong showing across the Index reflects focused investments in care quality, physician leadership and a commitment to serving vulnerable and underserved populations. 'Social responsibility and health equity are not just goals—they are a reflection of our purpose as a healthcare organization,' said Sunny Bhatia, MD, President and Corporate Chief Medical Officer of Prime Healthcare. 'It is a profound responsibility and honor to care for our communities, and I commend our caregivers for the compassion, excellence and integrity they bring to every patient encounter.' Sixteen of the hospitals recognized this year are not-for-profit facilities supported by the Prime Healthcare Foundation, reinforcing the Foundation's mission to expand access and advance health equity in underserved communities. 'We are proud of the extraordinary physicians and staff at our Foundation hospitals who bring our mission to life each day,' said Kavitha Bhatia, MD, President and Chair of the Prime Healthcare Foundation. 'Their unwavering commitment to compassionate, high-quality care ensures that dignity, respect and equity remain central to every patient experience. This recognition is a testament to their leadership and dedication.' Four Prime Healthcare hospitals earned a spot on the prestigious Lown Institute Honor Roll, receiving straight 'A' grades across all measured categories, including Social Responsibility, Health Equity, Value of Care and Patient Outcomes: The Lown Hospitals Index for Social Responsibility is the only ranking to combine metrics of health equity and value of care alongside patient outcomes for more than 2,700 acute care and 800 critical access hospitals nationwide, offering a holistic view of hospitals as total community partners. In the sixth annual rankings, the 2025-26 Lown Index evaluates hospitals on over 50 measures including novel metrics such as community benefit, racial inclusivity, and avoidance of overuse. Data sources include Medicare fee-for-service and Medicare Advantage claims, CMS patient safety data and hospital cost reports, and IRS 990 forms, among others. Full methodology can be found on the Lown Index website. The full list of the 46 Prime Healthcare/Prime Healthcare Foundation 2025-26 Lown Institute Hospitals Index awardees is as follows: Centinela Hospital Medical Center, Inglewood, CA; Chino Valley Medical Center; Chino, CA; Coshocton Regional Medical Center, Coshocton, OH; Dallas Medical Center, Dallas, TX; Dallas Regional Medical Center, Mesquite, TX; Desert Valley Hospital, Victorville, CA; East Liverpool City Hospital, East Liverpool, OH; Encino Hospital Medical Center, Encino, CA; Garden City Hospital, Garden City, MI; Garden Grove Hospital Medical Center, Garden Grove, CA; Harlingen Medical Center, Harlingen, TX; Huntington Beach Hospital, Huntington Beach, CA; Knapp Medical Center, Weslaco, TX; La Palma Intercommunity Hospital, La Palma, CA; Lake Huron Medical Center, Port Huron, MI; Landmark Medical Center, Woonsocket, RI; Lehigh Regional Medical Center, Lehigh Acres, FL; Lower Bucks Hospital, Bristol, PA; Mercy Medical Center, Aurora, IL; Mission Regional Medical Center, Mission, TX; Monroe Hospital, Bloomington, IN; Montclair Hospital Medical Center, Montclair, CA; North Vista Hospital, North Las Vegas, NV; Paradise Valley Hospital, National City, CA; Providence Medical Center, Kansas City, KS; Resurrection Medical Center, Chicago, IL; Riverview Regional Medical Center, Gadsden AL; Roxborough Memorial Hospital, Philadelphia, PA; Saint Clare's Denville, Denville, NJ; Saint Francis Hospital, Evanston, IL; Saint Joseph Hospital, Elgin, IL; Saint Joseph Medical Center, Joliet, IL; Saint Mary of Nazareth Hospital, Chicago, IL; Saint Mary's Regional Medical Center, Reno, NV; Saint Michael's Medical Center, Newark, NJ; San Dimas Community Hospital, San Dimas, CA; Shasta Regional Medical Center, Redding, CA; Sherman Oaks Hospital, Sherman Oaks, CA; Southern Regional Medical Center, Riverdale, GA; St. Francis Medical Center, Lynwood, CA; St. Joseph Medical Center, Kansas City, MO; St. Mary's General Hospital, Passaic, NJ; St. Mary's Hospital, Kankakee, IL; St. Mary's Medical Center, Kansas City, MO; Suburban Community Hospital, Norristown, PA; West Anaheim Medical Center, Anaheim, CA. About Prime Healthcare and Prime Healthcare Foundation Prime Healthcare is an award-winning health system operating 51 hospitals and more than 360 outpatient locations in 14 states, providing over 2.5 million patient visits annually. It is one of the nation's leading health systems, with nearly 57,000 employees and physicians. Eighteen of the Prime Healthcare hospitals are members of the Prime Healthcare Foundation, a 501(c)(3) not-for-profit public charity. Based in Ontario, California, Prime Healthcare is nationally recognized for award-winning quality care and has been named a 10 Top and 15 Top Health System by Truven Health Analytics. Its hospitals have been named among the nation's '100 Top Hospitals' 72 times and is one of Healthgrades most awarded health systems in the nation for patient safety. To learn more, please visit
